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AbstrAct
Traditional randomised controlled trials that rely on research staff to collect data are becoming increasingly expensive. 
As a result, the number of interventions that can be scrutinised for effectiveness will be limited. Further, while results 
from such trials have high internal validity, they will have limited external validity – generalisability to the real-world 
population. One solution is to adopt a more pragmatic approach and embed randomisation into routine healthcare 
databases such as registries. There are a number of ways that this can be done. Most commonly, registries simply 
provide extended follow-up to traditional explanatory trials, but with the necessary permissions more novel 
approaches are possible. Registries can be used to identify potentially eligible participants, provide the baseline data 
and provide all of the follow-up data. Proportionate to the risk associated with the intervention, routine healthcare 
databases can also provide some of the safety monitoring data, greatly reducing the burden and cost of the trial. 
To illustrate the opportunities and challenges, a number of reported and ongoing registry trials are presented.
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INtrODUctION
For decades, randomised controlled trials (RCTs) have 
been considered the most robust form of primary 
research on which to base treatment recommenda- 
tions [1]. However, people with kidney disease are often 
excluded from trials of common conditions such as 
cardiovascular disease and osteoporosis [2,3]. For trials 
focused on kidney disease, nephrology sits at the bottom 
of the league table [4], and even in those trials, partici-
pants tend to be unrepresentative of the wider kidney 
patient population [5].
The generalisability criticism is, of course, not unique to 
nephrology and as far back as the 1960s it was recognised 
that there needed to be two different types of trials – 
explanatory and pragmatic [6].
•   Explanatory trials, which maximise the intervention’s 
chance of demonstrating an effect through the 
expected mechanism, with little attention paid to the 
issue of whether this outcome would be achieved 
under real-world conditions, either locally or in more 
distant settings.
•   Pragmatic trials, which maximise applicability of the 
intervention to usual care across a range of local and 
distant settings [7].
Another problem with RCTs is the total cost, which can 
run into tens to hundreds of millions of dollars on the 
rare occasions that it is reported [8]. Such costs limit 
trials to evaluations of products – pharmaceutical or 
device – with the potential to generate profit that will 
recoup those costs. Limiting RCTs to these novel 
interventions misses a huge opportunity to critically 
evaluate and evolve existing practice to optimise out-
comes for patients and the healthcare economy.
One way to mitigate both the generalisability and the 
financial risks of RCTs in nephrology is to rely more on 
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routinely collected data for everything from the identification 
of potential participants to assessing trial outcomes. If per-
missions allow, these routine data could include electronic 
health records, prescribing databases, billing databases, 
device registries or disease registries. Such RCTs are 
hereafter referred to as ‘registry trials’. This paper will first 
consider some of the strengths and limitations of registry 
RCTs before looking at examples of renal and non-renal 
registry RCTs that have been completed or are in progress.
ADVANtAGEs AND cHALLENGEs OF 
rEGIstrY rcts
The advantages of registry RCTs can be summarised as 
lower cost, enhanced generalisability, consecutive enrol-
ment and completeness of follow-up. Figure 1 compares 
and contrasts registry-based RCTs with traditional RCTs 
[9-11].
The costs of a registry RCT are minimised in several ways. 
Recruitment is often easier and quicker as the eligibility 
criteria are wide and many more patients can be invited to 
participate. Depending on information governance per-
missions, it may even be possible to use the registry to 
identify eligible patients and approach them to explore 
their willingness to take part. Another major saving comes 
from reducing traditional data capture activity by replacing 
the formal data collection procedures at baseline and/or 
follow-up with data collected routinely from one or 
multiple routine data sources. Depending on the inter-
vention being tested, it may also be possible to rely on 
prospective routine data collection for some of the 
monitoring of adverse events that occur with participants 
like hospital admissions, deaths, serious adverse reactions 
(events that are considered to have been a direct effect of 
the intervention) and serious adverse events (events that 
are considered not to have been a direct effect of the 
intervention). The extent to which this can be done must 
be proportionate to what is known already about the risks 
associated with the intervention being tested [12]. For 
example, vitamin D has been judged safe for the public to 
purchase without a prescription, so while safety monitoring 
is clearly required it would seem disproportionate to 
require expedited detailed capture of all adverse events in 
a trial of vitamin D versus placebo in dialysis patients.
A major criticism of explanatory trials is that while they may 
have very high internal validity – that is,  in a highly selected 
trial cohort with limited possible external factors the 
intervention is effective – they have low external validity, 
meaning that in the patients coming to clinic today the 
intervention is much less likely to be effective. By having 
very wide eligibility criteria, registry RCTs include cohorts 
of patients much more representative of the real world. 
Embedding randomised controlled trials in renal registries
Figure 1.  Venn diagram illustrating the relationship between, and characteristics of, traditional pragmatic rcts, 
explanatory rcts and registry-based rcts. 
abbreviation: Rct = randomised controlled trial. 
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External factors such as adherence with the treatment are 
also less aggressively controlled and more like what would 
be expected in the real world. The results from pragmatic 
registry RCTs are therefore more likely to be observed as 
the interventions are rolled out into routine practice.
Some registries have permissions to be used to screen for 
patients who meet the eligibility criteria and so can be 
used to identify consecutive patients, thus reducing 
selection bias. Large registry cohorts offer the opportunity 
to perform nested randomized trials for multiple inter-
ventions simultaneously. This is known as a cohort multiple 
RCT [13]. Most commonly, however, registries are used to 
provide long-term follow-up and where there is national 
coverage they bring the major advantage of exceedingly 
low rates of loss to follow-up [14].
Registry RCTs have their challenges too, however. Broadly 
speaking, these can be summarised as related to data 
quality, information governance permissions and method-
ological challenges.
The primary purpose of most registries is not research, and 
so the same rigour is not applied to data capture and 
validation as would traditionally have been expected of 
RCTs. While data dictionaries may exist, the validity of the 
data still relies on the reliability of clinical staff routinely 
entering the data. A great deal of attention therefore needs 
to be paid to the evidence of completeness and validity of 
any registry data before deciding on a registry RCT 
approach [15]. Most obviously, this will influence the choice 
of end-point and the ability to adjust for baseline con-
founders. It is also worth reflecting on the registry’s ability 
to routinely monitor adherence to treatment – or com-
ponents of treatment for a complex intervention – which 
becomes very pertinent when interpreting the results of 
the RCT, particularly if the result is null.
For the same reasons, the existing information governance 
approvals – providing compliance with data protection law 
and the Declaration of Helsinki – will almost certainly not 
permit interventional studies. In this regard the landscape 
differs from jurisdiction to jurisdiction and general advice is 
hard to give. As well as the usual research ethics approvals, 
it will be necessary to ensure that all data protection laws 
are complied with. In some countries, laws are more 
accommodating than in others, which explains why more 
than half of all registry RCTs identified in a recent systematic 
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Figure 2.  Flow diagrams illustrating different ways in which registry data may be utilised in rcts. A represents 
rcts run entirely within a registry; b and c represent rcts that combine traditional rct methodology with 
registry methodology; D shows rcts run entirely in a trials unit. 
abbreviation: Rct = randomised controlled trial. 
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review had been conducted in Denmark or Sweden [14]. 
Data protection compliance becomes particularly chal-
lenging when data from more than one source need to be 
linked.
From a methodological perspective there are also several 
challenges. As discussed above, choice of end-point will be 
affected by the available data and their quality. Adjudication 
of end-points will not be the norm, though this may be less 
important for outcomes arising from routine data [16]. For 
both of these reasons there is likely to be lower precision 
around the effect estimate in a registry RCT, which will 
have implications for sample size calculations. While event 
rates may be greater in real-world data [5], and this may 
give the impression of greater statistical power, it is 
important to weigh this against the high chance that events 
not likely to be affected by the intervention will attenuate 
any effect. 
There are number of ways in which registry data may be 
incorporated into an RCT study design. It may be possible 
to carry out enrolment, allocation, randomisation and 
follow-up within the registry framework. Alternatively, 
registries may provide follow-up data in traditional RCTs 
(see Figure 2) [17].
rEGIstrY rcts tHAt HAVE bEEN 
cOMPLEtED AND sOME tHAt ArE 
UNDEr WAY
In a 2017 systematic review, only 71 registry RCTs were 
identified across all specialities [14]. For readers looking for 
more case studies to learn from, the full list of published 
registry RCTs is available in the supplementary material of 
the paper, but a few are worth highlighting.
The Swedish Web System for Enhancement and Devel-
opment of Evidence-based Care in Heart Disease Evaluated 
According to Recommended Therapies (SWEDEHEART) 
registry [18] provides a powerful illustration of what can be 
achieved with a registry platform capable of supporting 
RCTs. SWEDEHEART collects data via a web-based data 
entry system on consecutive patients presenting with acute 
coronary syndrome or undergoing coronary angiography/
angioplasty or heart surgery across all 74 hospitals providing 
this service in Sweden [18]. Each year a validation exercise 
is undertaken on a random sample of 30–40 cases in 20 
of these hospitals. Using this platform, SWEDEHEART 
has been able to conduct large RCTs looking at highly 
clinically relevant interventions such as manual thrombus 
aspiration in patients with acute myocardial infarction 
undergoing percutaneous intervention (TASTE, 7,244 
patients) [19] and bivalirudin or heparin during percuta-
neous coronary intervention (VALIDATE-SWEDEHEART, 
6,006 patients) [20]. By relying on routine registry data 
for baseline and follow-up data, SWEDEHEART has an 
impressive track record of keeping costs low – TASTE 
reportedly cost only $350,000 in total, which equates to 
$50 per recruited patient [21].
In nephrology, registries have been used to provide long-
term follow-up data beyond the end of the original 
traditional RCT. A recent, but still early, example was the 
use of linkage to a number of routine databases to provide 
the outcomes for one of the randomisation arms in the 
Campath, Calcineurin inhibitor reduction, and Chronic 
allograft nephropathy (3C) study, which randomised kidney 
transplant recipients to tacrolimus or sirolimus mainte-
nance therapy [22]. Linking to a number of databases in the 
UK – Hospital Episode Statistics, Office for National 
Statistics, UK Transplant and UK Renal Registry – the 
researchers were able to obtain follow-up data on graft 
function (serum creatinine), graft failure, patient survival, 
cancer and cause-specific mortality.
Routine data can also be used to evaluate more complex 
interventions delivered at a ward, hospital or renal unit 
level, with randomisation occurring at the level of the 
‘cluster’. Two such trials addressing kidney health outcomes 
are worth considering. The first is the Primary-Secondary 
Care Partnership to Improve Outcomes in Chronic Kidney 
Disease (PSP-CKD) study, which rolled out a nurse-led 
CKD management programme aimed at improving out-
comes in patients with CKD in primary care [23]. Forty-six 
primary care practices were provided with the IMPAKT 
CKD software to help manage CKD before being randomly 
allocated to receive or not receive an experienced CKD 
nurse practitioner to support an allocated CKD clinical 
lead. Outcomes were extracted from the routine primary 
care data by the IMPAKT software and included change in 
mean eGFR (at the practice level) over 42 months as 
well as blood pressure control and recognition of CKD. 
Although processes of care associated with improved long-
term outcomes improved, no significant improvement was 
observed in the mean eGFR at the practice level [23].
When it might be harder to get sites to agree to being 
randomised to the control arm, an alternative cluster design 
is a stepped-wedge cluster RCT. With this approach, all 
sites are exposed to the intervention, but the order in 
which they adopt the intervention is determined at random. 
This was the design of the Tackling Acute Kidney Injury 
(Tackling AKI) study in which a 3-component complex 
intervention – AKI e-alerts, a care bundle and an education 
package – was rolled out across five hospitals in England 
with the aim of reducing mortality [24]. Despite a promising 
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30% reduction in hospital-level mortality being observed 
in a single-centre pilot study, and 24,059 AKI episodes with 
a 30-day mortality of 24.5%, the intervention did not 
appear to have any effect on 30-day mortality in the trial. 
As with PSP-CKD, however, significant improvements were 
observed in processes of care and there was evidence of 
reduced length of hospital stay [24].
Of course, RCTs, even registry RCTs, have a long gestation 
period and it is worth noting that there are several kidney-
focused registry RCTs which are funded and under way, 
and expected to report the results in the next few years. 
For example:
•   The Natural vitamin D (cholecalciferol) versus standard 
care in patients receiving dialysis – The SIMPLIFIED 
randomised registry trial, which is collecting baseline 
data traditionally, but with all follow-up through data 
linkage including the highly innovative linkage with weekly 
laboratory data feeds from the UK Renal Registry [25]. 
The study is funded by the National Institute for Health 
Research, has a recruitment target of 4,200 patients 
from 36 UK hospitals with 5 years of planned follow-up 
and has all-cause mortality as the primary outcome.
•   The High-volume HDF versus High-flux HD Registry 
Trial (H4RT), which is collecting baseline data tradition-
ally with research nurses and case report forms, but 
then manages all follow-up through linkage to routine 
data [26]. It is funded by the National Institute for Health 
Research, has a recruitment target of 1,550 from 30 UK 
hospitals with up to 4.5 years of follow-up and has a 
composite primary end-point of non-cancer death or 
admission to hospital with a cardiovascular- or infection-
related event.
•   The Better Evidence for Selecting Transplant Fluids 
(BEST-Fluids) trial, which is evaluating the effect, in 
deceased donor kidney transplant recipients, of intra-
venous therapy with Plasmalyte® versus 0.9% saline on 
delayed graft function following deceased donor kidney 
transplantation. Participants will be enrolled, randomised 
and followed up using ANZDATA, the Australia & New 
Zealand Dialysis & Transplant Registry [27]. It is funded 
by the National Health and Medical Research Council of 
Australia with a recruitment target of 800.
cONcLUsIONs
There are real opportunities to embed RCTs in routinely 
collected healthcare data and these should be possible in 
nephrology in particular given the established infrastructure 
and expertise in renal registries in many countries. The data 
protection laws in some countries make this easier than 
in others, but if these can be worked through it is possible 
to create platforms with cohorts from which patients can 
be screened and assessed for eligibility before being offered 
participation in these pragmatic trials. Although the 
relatively low costs look appealing, they rely on investment 
in and support of the infrastructure – the renal registries.
With all those caveats, registries provide a very exciting 
opportunity to increase the number of RCTs being under-
taken in nephrology and generate better quality evidence 
for us to improve the quality of care and outcomes for 
people with kidney disease.
rEFErENcEs
1.    Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. 
Users’ guides to the medical literature. IX. A method for grading 
health care recommendations. Evidence-Based Medicine Working 
Group. JAMA. 1995; 274:1800-1804.
2.    Wilson LM, Rebholz CM, Jirru E, Liu MC, Zhang A, Gayleard J, et al. 
Benefits and harms of osteoporosis medications in patients with 
chronic kidney disease: a systematic review and meta-analysis.  
Ann Intern Med. 2017; 166:649-658.
3.    Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS,  
Boden WE, et al. Diagnosis and management of atherosclerotic 
cardiovascular disease in chronic kidney disease: a review.  
Kidney Int. 2017; 91:797-807.
4.    Strippoli GFM, Craig JC, Schena FP. The number, quality, and 
coverage of randomized controlled trials in nephrology. J Am Soc 
Nephrol. 2004; 15:411-419.
5.    Smyth B, Haber A, Trongtrakul K, Hawley C, Perkovic V,  
Woodward M, et al. Representativeness of randomized clinical trial 
cohorts in end-stage kidney disease: a meta-analysis. JAMA Intern 
Med. 2019; 179(10):1316-1324.
6.    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in 
therapeutical trials. J Clin Epidemiol. 2009; 62:499-505.
7.    Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein 
M. The PRECIS-2 tool: designing trials that are fit for purpose.  
BMJ. 2015; 350:h2147.
8.    Speich B, von Niederhausern B, Schur N, Hemkens LG, Furst T, 
Bhatnagar N, et al. Systematic review on costs and resource use  
of randomized clinical trials shows a lack of transparent and 
comprehensive data. J Clin Epidemiol. 2018; 96:1-11.
9.    Verkooijen H, Roes K. Cohort multiple randomized controlled trial:  
a solution for the evaluation of multiple interventions. Ned Tijdschr 
Geneeskd. 2013; 157:A5762-A5762.
10.  Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S,  
Haynes B, et al. Improving the reporting of pragmatic trials: an 
extension of the CONSORT statement. BMJ. 2008; 337:a2390.
11.  Dal-Ré R, Janiaud P, Ioannidis JP. Real-world evidence: How 
pragmatic are randomized controlled trials labeled as pragmatic? 
BMC Med. 2018; 16:49.
12.  Irving E, van den Bor R, Welsing P, Walsh V, Alfonso-Cristancho R, 
Harvey C, et al. Series: Pragmatic trials and real world evidence: 
Paper 7. Safety, quality and monitoring. J Clin Epidemiol.  
2017; 91:6-12.
13.  Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic 
randomised controlled trials: introducing the "cohort multiple 
Embedding randomised controlled trials in renal registries
59
randomised controlled trial" design. BMJ. 2010; 340:c1066.
14.  Mathes T, Buehn S, Prengel P, Pieper D. Registry-based randomized 
controlled trials merged the strength of randomized controlled trails 
and observational studies and give rise to more pragmatic trials.  
J Clin Epidemiol. 2018; 93:120-127.
15.  Lauer MS, D'Agostino RB, Sr. The randomized registry trial - the next 
disruptive technology in clinical research? N Engl J Med. 2013; 
369:1579-1581.
16.  Ndounga Diakou LA, Trinquart L, Hrobjartsson A, Barnes C,  
Yavchitz A, Ravaud P, et al. Comparison of central adjudication  
of outcomes and onsite outcome assessment on treatment effect 
estimates. Cochrane Database Syst Rev. 2016; 3:MR000043.
17.  Nyberg K, Hedman P. Swedish guidelines for registry-based 
randomized clinical trials. Ups J Med Sci. 2019; 124:33-36.
18.  Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, 
et al. The Swedish Web-system for enhancement and development 
of evidence-based care in heart disease evaluated according to 
recommended therapies (SWEDEHEART). Heart. 2010;  
96:1617-1621.
19.  Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, 
Maeng M, et al. Thrombus aspiration during ST-segment elevation 
myocardial infarction. N Engl J Med. 2013; 369:1587-1597.
20.  Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M,  
Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial 
infarction. N Engl J Med. 2017; 377:1132-1142.
21.  Wachtell K, Lagerqvist B, Olivecrona GK, James SK, Fröbert O.  
Novel trial designs: lessons learned from thrombus aspiration during 
ST-segment elevation myocardial infarction in Scandinavia (TASTE) 
trial. Curr Cardiol Rep. 2016; 18:11.
22.  The 3C Study Collaborative Group. Campath, calcineurin inhibitor 
reduction, and chronic allograft nephropathy (the 3C Study) - results 
of a randomized controlled clinical trial. Am J Transplant. 2018; 
18:1424-1434.
23.  Major RW, Brown C, Shepherd D, Rogers S, Pickering W,  
Warwick GL, et al. The primary-secondary care partnership to 
improve outcomes in chronic kidney disease (PSP-CKD) study:  
a cluster randomized trial in primary care. J Am Soc Nephrol.  
2019; 30:1261-1270.
24.  Selby NM, Casula A, Lamming L, Stoves J, Samarasinghe Y,  
Lewington AJ, et al. An organizational-level program of intervention 
for AKI: a pragmatic stepped wedge cluster randomized trial.  
J Am Soc Nephrol. 2019; 30:505-515.
25.  Natural vitamin D (cholecalciferol) versus standard care in patients 
receiving dialysis - The SIMPLIFIED randomised registry trial. http://
www.isrctn.com/ISRCTN15087616. Accessed 23 October 2019.
26.  The High-volume Haemodiafiltration vs High-flux Haemodialysis 
Registry Trial. https://www.journalslibrary.nihr.ac.uk/programmes/
hta/158052/#/. Accessed 02 January 2018.
27.  Better Evidence for Selecting Transplant Fluids (BEST-Fluids).  
www.aktn.org.au/best-fluids. Accessed 18 July 2019.
Embedding randomised controlled trials in renal registries
